Godavari Drugs Ltd
Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates[1]
- Market Cap ₹ 79.0 Cr.
- Current Price ₹ 105
- High / Low ₹ 114 / 82.1
- Stock P/E 14.1
- Book Value ₹ 51.8
- Dividend Yield 0.00 %
- ROCE 14.6 %
- ROE 15.5 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 79.0 days to 113 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | 9 | 55 | 71 | 76 | 64 | 84 | 96 | 123 | 161 | 160 | 157 | |
6 | 8 | 49 | 67 | 70 | 60 | 78 | 90 | 113 | 150 | 150 | 143 | |
Operating Profit | 2 | 2 | 6 | 4 | 5 | 4 | 5 | 6 | 10 | 11 | 10 | 13 |
OPM % | 21% | 20% | 11% | 6% | 7% | 6% | 7% | 6% | 8% | 7% | 6% | 8% |
0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | |
Interest | 0 | 0 | 1 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 5 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
Profit before tax | 1 | 1 | 5 | 2 | 3 | 1 | 2 | 2 | 6 | 7 | 5 | 7 |
Tax % | 33% | -121% | 23% | 38% | 33% | 37% | 31% | 13% | 28% | 25% | 23% | 20% |
0 | 2 | 4 | 1 | 2 | 1 | 1 | 2 | 4 | 5 | 4 | 6 | |
EPS in Rs | 0.64 | 2.06 | 4.85 | 1.79 | 2.40 | 1.10 | 1.61 | 2.66 | 5.48 | 6.97 | 5.03 | 7.37 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 32% |
5 Years: | 13% |
3 Years: | 9% |
TTM: | -2% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 36% |
3 Years: | 11% |
TTM: | 56% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 36% |
3 Years: | 17% |
1 Year: | 12% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 15% |
3 Years: | 15% |
Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Reserves | 0 | 2 | 6 | 7 | 9 | 10 | 11 | 13 | 17 | 22 | 26 | 31 |
2 | 2 | 8 | 16 | 16 | 19 | 22 | 28 | 30 | 23 | 36 | 56 | |
5 | 3 | 13 | 21 | 24 | 27 | 33 | 36 | 36 | 49 | 52 | 40 | |
Total Liabilities | 15 | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 |
7 | 8 | 7 | 9 | 13 | 15 | 15 | 14 | 22 | 26 | 25 | 27 | |
CWIP | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 9 | 1 | 0 | 9 | 18 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
7 | 7 | 27 | 41 | 43 | 47 | 57 | 61 | 68 | 75 | 87 | 90 | |
Total Assets | 15 | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | -6 | -5 | 5 | 4 | 4 | 6 | 1 | 11 | 13 | 18 | |
-1 | -2 | -0 | -2 | -3 | -3 | -2 | -7 | -1 | -5 | -9 | -13 | |
1 | 0 | 6 | 7 | -2 | -0 | -1 | 0 | 0 | -6 | -4 | -6 | |
Net Cash Flow | 0 | -0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | 1 | 1 | -0 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 32 | 20 | 87 | 126 | 117 | 152 | 148 | 137 | 134 | 126 | 132 | 138 |
Inventory Days | 1,484 | 973 | 84 | 67 | 70 | 100 | 93 | 84 | 55 | 28 | 57 | 62 |
Days Payable | 284 | 179 | 79 | 108 | 124 | 171 | 171 | 144 | 112 | 121 | 132 | 96 |
Cash Conversion Cycle | 1,231 | 814 | 92 | 85 | 63 | 81 | 70 | 78 | 78 | 33 | 58 | 105 |
Working Capital Days | 147 | 120 | 95 | 104 | 95 | 112 | 95 | 88 | 86 | 52 | 73 | 113 |
ROCE % | 9% | 8% | 32% | 16% | 17% | 11% | 12% | 12% | 18% | 18% | 14% |
Documents
Announcements
- Closure of Trading Window 26 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - News Paper clippings of Audited Financial Results for the Quarter and Year Ended March 31st, 2024
- Financial Results For The Quarter And Year Ended On 31St March 2024 30 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Secretarial Compliance Report for the Financial Year ended March 31, 2024
- Board Meeting Outcome for Outcome Of Board Meeting 30 May
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Company is in the business of Manufacturing APIs, drug intermediaries, and fine chemicals and caters to the global Life Science Industry. It has an active Loan License and Contract Manufacturing tie-ups with multinational companies for APIs and drug intermediates